Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | STS | P08842 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298228 | 0.89 | ADORA1 (0.43) | NR1H2ESR2ADORA1MAPTSTS | |
| SCHEMBL556981 | 0.88 | ADORA1 (0.47) | NR1H2ESR2ADORA1STSSMN1; SMN2 | |
| SCHEMBL13382352 | 0.83 | ESR2 (0.41) | NR1H2ESR2ADORA1MAPTSTS | |
| SCHEMBL12354131 | 0.80 | ESR2 (0.39) | NR1H2ESR2ADORA1MAPTSTS | |
| SCHEMBL13382410 | 0.80 | TMEM97 (0.46) | SMN1; SMN2 | |
| SCHEMBL8232783 | 0.80 | ADORA1 (0.43) | ADORA1STSUSP2SMN1; SMN2 | |
| SCHEMBL19874374 | 0.79 | NR1H2 (0.36) | NR1H2ESR2ADORA1MAPTSTS | |
| SCHEMBL19874372 | 0.79 | NR1H2 (0.36) | NR1H2ESR2ADORA1MAPTSTS | |
| SCHEMBL16050467 | 0.79 | ESR2 (0.39) | NR1H2ESR2ADORA1MAPTSTS | |
| SCHEMBL8252328 | 0.79 | NR1H2 (0.42) | NR1H2ESR2ADORA1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3919056-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| CN-109923116-B | [1,2,4] triazolo [1,5-a ] pyrimidine derivatives as PDE2 inhibitors | 詹森药业有限公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-3919056-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-2970308-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| CN-111454200-A | Compounds and their use for modulating hemoglobin | 全球血液疗法股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-20190112287-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-04-18 | — | — | US | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
| EP-1620403-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-01 | — | — | EP | disclosed |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-12 | — | — | US | disclosed |
| EP-1404682-B1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK AS (DK) | 2005-09-14 | — | — | EP | disclosed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004105738-A2 | USE OF TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004096769-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | US | disclosed |
| US-5376666-A | Hypotensive agents, angiotension antagonist, enzyme inhibitors , treating congestive heart failure | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | NR1H2 1090/4885ESR2 1597/4885ADORA1 3277/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | NR1H2 1090/4885ESR2 1597/4885ADORA1 3277/4885 |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | NR1H2 1090/4885ESR2 1597/4885ADORA1 3277/4885 |
| US-20190112287-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | NR1H2 1090/4885ESR2 1597/4885ADORA1 3277/4885 |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | REN, ACE, ACE2 | NR1H2 3093/4885ESR2 4049/4885ADORA1 1695/4885 |
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | PTPRO, PTPRF, PTPA | NR1H2 4602/4885ESR2 4443/4885ADORA1 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.